Clinical uses of melatonin: Evaluation of human trials

Current Medicinal Chemistry

Volumn 17, Issue 19, 2010, Pages 2070-2095

  Sanchez Barcelo E J ^a   Mediavilla, M D ^a   Tan, D X ^b   Reiter, R J ^b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aging; Anesthesia; Arterial hypertension; Chronic fatigue syndrome; Clinical trials; Crohn's disease; Depression; Diabetes; Fibromyalgia; Gastric mucosa; Glaucoma; Hemodialysis; In vitro fertilization; Infectious diseases; Irritable bowel syndrome; Jet lag; Macular degeneration; Melatonin; Neonatal care; Neurological diseases; Rheumatoid arthritis; Shift work; Sleep disturbances; Smith magenis syndrome; Ulcerative colitis

Indexed keywords

5 METHOXYINDOLEACETIC ACID; 5 METHOXYTRYPTAMINE; 5 METHOXYTRYPTOPHOL; ACICLOVIR; BROMOCRIPTINE; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FATTY ACID; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 2; IRINOTECAN; MAGNESIUM; MELATONIN; MESALAZINE; METFORMIN; MITOXANTRONE; MORPHINE; PACLITAXEL; PHOSPHATE; RETINOID; SOMATOSTATIN; TRIPTORELIN; UNINDEXED DRUG; VITAMIN D; ZINC ACETATE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADVANCED CANCER; AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANESTHESIA INDUCTION; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BEDTIME DOSAGE; BENIGN CHILDHOOD EPILEPSY; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOID; CHRONIC DRUG ADMINISTRATION; CHRONIC FATIGUE SYNDROME; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CLUSTER HEADACHE; COLORECTAL CANCER; DEPRESSION; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FIBROMYALGIA; GASTROINTESTINAL TUMOR; GLAUCOMA; HEAD AND NECK TUMOR; HEMODIALYSIS PATIENT; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; IRRITABLE COLON; JET LAG; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG CANCER; MENOPAUSE; METASTASIS; MIGRAINE; MULTIPLE CYCLE TREATMENT; NEWBORN CARE; PANCREAS ISLET CELL TUMOR; PARKINSON DISEASE; POSTOPERATIVE PAIN; PREMEDICATION; PROSTATE CANCER; RETINA MACULA DEGENERATION; RHEUMATOID ARTHRITIS; SENILE DEMENTIA; SEPSIS; SINGLE DRUG DOSE; SLEEP DISORDER; SMALL CELL CARCINOMA; SMITH MAGENIS SYNDROME; SOLID TUMOR; STOMACH PROTECTION; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT DURATION; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; UTERINE CERVIX CARCINOMA; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMMUNICABLE DISEASES; ENDOCRINE SYSTEM DISEASES; EYE DISEASES; FATIGUE SYNDROME, CHRONIC; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; MUSCULAR DISEASES; NEOPLASMS; NERVOUS SYSTEM DISEASES;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; ENDOCRINE SYSTEM DISEASES; EYE DISEASES; FATIGUE SYNDROME, CHRONIC; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; MELATONIN; MUSCULAR DISEASES; NEOPLASMS; NERVOUS SYSTEM DISEASES;

EID: 77953482835     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791233689     Document Type: Article

References (261)

1. Lerner, A.B.; Case, J.D.; Takahashi, Y.; Lee, Y.; Mori, W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J. Am. Chem. Soc., 1958, 80, 2587.
2. Cardell, M.; Jung, F.J.; Zhai, W.; Hillinger, S.; Welp, A.; Manz, B.; Weder, W.; Korom, S. Acute allograft rejection and immunosup-pression: influence on endogenous melatonin secretion. J. Pineal Res., 2008, 44, 261-266.
3. Samantaray, S.; Sribnick, E.A.; Das, A.; Knaryan, V.H.; Matzelle, V.D.; Yallapragada, A.V.; Reiter, R.J.; Ray, S.K.; Banik, N.L. Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. J. Pineal Res., 2008, 44, 348-357.
4. Koh, P.O. Melatonin prevents the injury-induced decline of Akt/fork head transcription factors phosphorylation. J. Pineal Res., 2008, 44, 101-106.
5. Konturek, P.C.; Konturek, S.J.; Burnat, G.; Brzozowski, T.; Brzozowska, I.; Reiter, R.J. Dynamic physiological and molecular changes in gastric ulcer healing achieved by melatonin and its precursor L-tryptophan in rats. J. Pineal Res., 2008, 45, 180-190.
6. Lin, C.H.; Huang, J.Y.; Ching, C.H.; Chuang, J.I. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J. Pineal Res., 2008, 44, 205-213.
7. Tengattini, S.; Reiter, R.J.; Tan, D.X.; Terron, M.P.; Rodella, L.F.; Rezzani, R. Cardiovascular diseases: protective effects of melatonin. J. Pineal Res., 2008, 44, 16-25.
8. Peschke, E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res., 2008, 44, 26-40.
9. Olcese, J.M.; Cao, C.; Mori, T.; Mamcarz, M.B.; Maxwell, A.; Runfeldt, M.J.; Wang, L.; Zhang, C.; Lin, X.; Zhang, G.; Arendash, G.W. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res., 2009, 47, 82-96.
10. Nagle, C.A.; Cardinali, D.P.; Rosner, J.M. Retinal and pineal hydroxyindole-O-methyl transferases in the rat: changes following cervical sympathectomy, pinealectomy or blinding Endocrinology, 1973, 92, 1560-1564.
11. Iuvone, P.M.; Tosini, G.; Pozdeyev, N.; Haque, R.; Klein, D.C.; Chaurasia, S.S. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog. Retin. Eye Res., 2005, 24, 433-456.
12. Blazynski, C.; Dubocovich, M. Localisation of 2-[I125]-iodomelatonin binding sites in the mammalian retina. J. Neuro-chem., 1991, 57, 685-689.
13. Pang, S.F.; Yew, D.T. Pigment aggregation by melatonin in the retinal pigment epithelium and choroid of guinea pigs Cavia porcellus. Experientia, 1979, 35, 213-233.
14. Kaur, C.; Foulds, W.S.; Ling, E.A. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog. Retin. Eye Res., 2008, 27, 622-647.
15. Osborne.; N.N.; Chidlow, G. The presence of functional melatonin receptors in the iris-ciliary processes of the rabbit eye. Exp. Eye Res., 1994, 59, 3-9.
16. Pintor, J.; Martin, L.; Pelaez, T.; Hoyle, C.H.; Peral, A. Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. Eur. J. Pharmacol., 2001, 416, 251-254.
17. Yi, C.; Pan, X.; Yan, H.; Guo, M.; Pierpaoli, W. Effects of melatonin in age-related macular degeneration. Ann. NY Acad. Sci., 2005, 1057, 384-392.
18. Samples, J.R.; Krause, G.; Lewy, A.J. Effect of melatonin on intraocular pressure. Curr. Eye Res., 1988, 7, 649-653.
19. Ismail, S.A.; Mowafi, H.A. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth. Analg., 2009, 108,1146-51.
20. Andrés-Guerrero, V.; Alarma-Estrany, P.; Molina-Martínez, I.T.; Peral, A.; Herrero-Vanrell, R.; Pintor, J. Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT. J. Exp. Eye Res., 2009, 88, 504-511.
21. Del Zar, M.M.; Martinuzzo, M.; Falcon, C.; Cardinali, D.P.; Carreras, L.O.; Vacas, M.I. Inhibition of human platelet aggregation and thromboxane-B2 production by melatonin: evidence for a diurnal variation. J. Clin. Endocrinol. Metab., 1990, 70, 246-251.
22. Dahm, A.; Osterud, B.; Hjeltnes, N.; Sandset, P.M.; Iversen P.O. Opposite circadian rhythms in melatonin and tissue factor pathway inhibitor type 1: does daylight affect coagulation? J. Thromb. Haemost., 2006, 4, 1840-1842.
23. Wirtz, P.H.; Spillmann, M.; Bärtschi, C.; Ehlert, U.; von Känel, R. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. J. Pineal Res., 2008, 44, 127-33.
24. Wirtz, P.H.; Bärtschi, C.; Spillmann, M.; Ehlert, U.; von Känel, R. Effect of oral melatonin on the procoagulant response to acute psychosocial stress in healthy men: a randomized placebo-controlled study. J. Pineal Res., 2008, 44, 358-65.
25. Lissoni, P.; Tancini, G.; Barni, S.; Paolorossi, F.; Rossini, F.; Maffé, P.; Di Bella, L. The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia. Recenti Prog. Med., 1996, 87, 582-585.
26. Huether, G. Melatonin synthesis in the gastrointestinal tract and the impact of nutritional factors on circulating melatonin. Ann. N.Y. Acad. Sci., 1994, 719, 146-158.
27. Jaworek, J.; Brzozowski, T.; Konturek, S.J. Melatonin as an organoprotector in the stomach and the pancreas. J. Pineal Res., 2005, 38, 73-83.
28. Tan, D.X.; Chen, L.D.; Poeggeler, B.; Manchester, L.C.; Reiter, R.J. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr. J., 1993, 1, 57-60.
29. Hardeland, R.; Tan, D.X.; Reiter, R.J. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J. Pineal Res., 2009, 47, 109-26.
30. Reiter, R.J.; Paredes, S.D; Manchester, L.C.; Tan, D.X. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. Crit. Rev. Biochem. Mol., Biol. 2009, 44, 125-200.
31. Klupińska, G.; Poplawski, T.; Drzewoski, J.; Harasiuk, A.; Reiter, R.J.; Blasiak, J.; Chojnacki, J. Therapeutic effect of melatonin in patients with functionaldyspepsia. J. Clin. Gastroenterol., 2007, 41, 270-274.
32. Klupińska, G.; Popawski, T.; Smigielski, J.; Basiak, J.; Chojnacki. The effect of melatonin on oxidative DNA damage in gastric mucosa cells of patients with functional dyspepsia. J. Pol. Merkur. Lekarski, 2009, 26, 366-369.
33. Konturek, P.C.; Celinski, K.; Slomka, M.; Cichoz-Lach, H.; Burnat, G.; Naegel, A.; Bielanski, W.; Konturek, J.W.; Konturek, S.J. Melatonin and its precursor L-tryptophan prevent acute gastric mucosal damage induced by aspirin in humans. J. Physiol. Pharmacol., 2008, 59, 67-75.
34. Andresen, V.; Camilleri, M. Irritable bowel syndrome: recent and novel therapeutic approaches. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs, 2006, 66, 1073-1088.
35. Barajas-Lopez, C.; Peres, A.L.; Espinosa-Luna, R.; Reyes-Vázquez, C; Prieto-Gómez, B. Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig sub-mucous plexus. Eur. J. Pharmacol., 1996, 312, 319-325.
36. + channels attenuated melatonin-induced relaxation of serotonin-contracted rat gastric fundus. Can. J. Physiol. Pha-macol., 2000, 78, 799-806.
37. Lu, W.Z.; Song, G.H.; Gwee, K.A.; Ho, K.Y. The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig. Dis. Sci., 2009, 54, 1087-1093.
38. Lu, W.Z.; Gwee, K.A.; Moochhalla, S.; Ho, K.Y. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study Aliment. Pharmacol. Ther., 2005, 22, 927-934.
39. Song, G.H.; Leng, P.H.; Gwee, K.A.; Moochhala, S.M.; Ho, K.Y. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut, 2005, 54, 1402-1407.
40. Saha, L.; Malhotra, S.; Rana, S.; Bhasin, D.; Pandhi, P. A preliminary study of melatonin in irritable bowel syndrome. J. Clin. Gastroenterol., 2007, 41, 29-32.
41. Farrell, R.J.; Peppercorn, M.A. Ulcerative colitis. Lancet, 2002, 359, 331-340.
42. Terry, P.D.; Villinger, F.; Bubenik, G.A.; Sitaraman, S.V. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflamm. Bowel Dis., 2009, 15, 134-140.
43. Mann, S. Melatonin for ulcerative colitis? Am. J. Gastroenterol., 2003, 98, 232-233.
44. Maldonado, M.D.; Calvo, J.R. Melatonin usage in ulcerative colitis: a case report. J. Pineal Res., 2008, 45, 339-40.
45. Calvo, J.R.; Guerrero, J.M.; Osuna, C.; Molinero, P.; Carrillo-Vico, A. Melatonin triggers Crohn's disease symptoms. J. Pineal Res., 2002, 32, 277-8.
46. Zanoboni, A.; Zanoboni-Muciaccia, W. Experimental hypertension in pinealectomized rats. Life Sci. 1967, 6, 2327-2331.
47. Hisada, T.; Ozono, S.; Sato, K.; Watanabe, Y.; Watanabe, M. Relationship between metabolic rhythm in the pineal body and the systemic blood pressure. IRCS J. Med. Sci., 1976, 4, 142-143.
48. Holmes, S.W.; Sugden, D. The effect of melatonin on pinealectomy-induced hypertension in the rat. Br. J. Pharmacol., 1976, 56, 360-361.
49. Reiter, R.J.; Tan, D.X.; Korkmaz, A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J. Hypertens., 2009, 27, S17-20.
50. Cagnacci, A.; Arangino, S.; Angiolucci, M.; Maschio, E.; Melis, G.B. Influences of melatonin administration on the circulation of women. Am. J. Physiol., 1998, 274, R335-R338.
51. Arangino, S.; Cagnacci, A.; Angiolucci, M.; Vacca, A.; Longu, G.; Volpe, A.; Melis, G.B. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am. J. Cardiol., 1999, 83, 1417-1419.
52. Zaslavskaia, R.M.; Shakirova, A.N.; Komarov, F.I.; Teǐblium, M.M.; Akhmetov, K.Z. Effects of melatonin alone and in combination with aceten on chronostructure of diurnal hemodynamic rhythms in patients with hypertension stage II. Ter. Arkh., 1999, 71, 21-24.
53. Zaslavskaia, R.M.; Komarov, F.I.; Shakirova, A.N.; Te blium, M.M.; Akhmetov, K.Z. Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hipertensión. Klin. Med., (Mosk.), 2000, 78, 41-44.
54. Zaslavskaia, R.M.; Biiasilov, N.S.; Akhmetov, K.Z.; Teblium, M.M. Capozide-50 alone and in combination with melatonin in therapy of hipertension. Klin. Med., (Mosk.), 2000, 78, 39-41.
55. Scheer, F.; van Montfrans, G.A.; van Someren, E.; Mairuhu, G.; Buijs, R.M. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension, 2004, 43, 192-197.
56. Cagnacci, A.; Cannoletta, M.; Renzi, A.; Baldassari, F.; Arangino, S.; Volpe, A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am. J. Hypertens., 2005, 18, 1614-1618.
57. Sewerynek, E. Melatonin and the cardiovascular system. Neuro Endocrinol. Lett., 2002, 23, 79-83.
58. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Garcia-Gonzalez, M.J.; Samimi-Fard, S.; Kaski, J.C.; Reiter, R.J. Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. J. Pineal Res., 2008, 44, 65-69.
59. Dominguez-Rodriguez, A.; Abreu-Gonzalez, P., Garcia-Gonzalez, M.J., Kaski, J.C.; Reiter R.J.; Jimenez-Sosa, A. A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty. The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemp. Clin. Trials., 2007, 28, 532-539.
60. Zaslavskaia, R.M.; Shcherban, E.A.; Logvinenko, S.I. Melatonin in combined therapy of patients with stable angina and arterial hypertension. Klin. Med., (Mosk.), 2008, 86, 64-67.
61. Rechciński, T.; Trzos, E.; Wierzbowska-Drabik, K.; Krzemińska-Pakuła, M.; Kurpesa, M. Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability. Hypertens. Res., 2010, 33(1):56-61.
62. Boden, G.; Ruiz, J.; Urbain, J.L.; Chen, X. Evidence for circadian rhythm of insulin secretion. Am. J. Physiol., 1996, 271, E246-E252.
63. Tutuncu, N.B.; Batur, M.K.; Yildiri, A.; Tutuncu, T.; Deger, A.; Koray, Z.; Erbas, B.; Kabalci, G.; Aksoyek, S.; Erbas, T. Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. J. Pineal Res., 2005, 39, 43-49.
64. Peschke, E.; Stumpf, I.; Bazwinsky, I.; Litvak, L.; Dralle, H.; Mühlbauer, E. Melatonin and type 2 diabetes - a possible link? J. Pineal Res., 2007, 42, 350-358.
65. Cagnacci, A.; Arangino, S.; Renzi, A.; Paoletti, A.M.; Melis, G.B.; Cagnaci, P.; Volpe, A. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin. Endocrinol., 2001, 54, 339-346.
66. Kadhim, H.M; Ismail, S.H.; Hussein, K.I.; Bakir, I.H.; Sahib, A.S.; Khalaf, B.H.; Hussein S.A. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. J. Pineal Res., 2006, 41, 189-193.
67. Hussain, S.A.; Khadim, H.M.; Khalaf, B.H.; Ismail, S.H.; Hussein, K.I.; Sahib, A.S. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med. J., 2006, 27, 1483-1488.
68. Carballo, A.; Daniels, S.R.; Dolan, L.M.; Khoury, J.C.; Bean, J.A. Blood pressure response to melatonin in type 1 diabetes. Pediatrics Diabetes, 2004, 5, 26-31.
69. Carballo, A.; Daniels, S.R.; Dolan, L.M.; Bean, J.A.; Khoury, J.C. Blood pressure-lowering effect of melatonin in type 1 diabetes. J. Pineal Res., 2004, 36, 262-266.
70. Robeva, R.; Kirilo, G.; Tomova, A.; Kumanov, P. Melatonininsulin interactions in patients with metabolic syndrome. J. Pineal Res., 2008; 44, 52-56.
71. Reiter, R.J.; Tan, D.X.; Osuna, C.; Gitto, E. Actions of melatonin in the reduction of oxidative stress. J. Biomed. Sci., 2000, 7, 444-458.
72. Kedziora-Kornatowsaka, K.; Szewczyk-Golec, K.; Kozakiewicz, M.; Pawluk, H.; Czuczejko, J.; Kornatowski, T.; Bartosz, G.; Kedziora J. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J. Pineal Res., 2009, 46, 333-337.
73. Carrillo-Vico, A.; Reiter, R.J.; Lardone, P.J.; Herrera, J.L.; Fernandez-Montesinos, R.; Guerrero, J.M.; Pozo, D. The modulatory role of melatonin on immune responsiveness. Curr. Opin. Investig. Drugs, 2006, 7, 423-431.
74. Hansson, I.; Holmdahl, R.; Mattsson, R. The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice. J. Neuroimmunol. 1992, 39, 23-30.
75. Forrest, C.M.; Mackay, G.M.; Stoy, N.; Stone, T.W.; Darlington, L.G. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br. J. Clin. Pharmacol., 2007, 64, 517-526.
76. Citera, G.; Arias, M.A.; Maldonado-Cocco, J.A.; Lázaro, M.A.; Rosemffet, M.G.; Brusco, L.I.; Scheines, E.J.; Cardinali, D.P. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin. Rheumatol., 2000, 19, 9-13.
77. Acuña-Castroviejo, D.; Escames, G.; Reiter, R.J. Melatonin therapy in fibromyalgia. J. Pineal Res., 2006, 40, 98-99.
78. Singh, A.; Garg, V.; Gupta, S.; Kulkarni, S.K. Role of antioxidants in chronic fatigue syndrome in mice. Ind. J. Exp. Biol., 2002, 40, 1240-1244.
79. Williams, G.; Waterhouse, J.; Mugarza, J.; Minors, D.; Hayden, K. Therapy of circadian rhythm disorders in chronic fatigue syndrome: no symptomatic improvement with melatonin or phototherapy. Eur. J. Clin. Invest., 2002, 32, 831-837.
80. van Heukelom, R.O.; Prins, J.B.; Smits, M.G.; Bleijenberg, G. Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion. Eur. J. Neurol., 2006, 13, 55-60.
81. Tekbas O.F.; Ogur R.; Korkmaz A.; Kilic A.; Reiter RJ. Melatonin as an antibiotic: new insights into the actions of this ubiquitous molecule. J. Pineal Res., 2008, 44, 222-226.
82. Escames, G.; Acuña-Castroviejo D.; López L.C.; Tan, D.X.; Maldonado, M.D.; Sánchez-Hidalgo, M.; León, J.; Reiter, R.J. Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence. J. Pharm. Pharmacol., 2006, 58, 1153-1165.
83. Gitto, E.; Karbownik, M.; Reiter, R. J.; Tan, D. X., Cuzzocrea, S.; Chiurazzi, P.; Cordaro, S.; Corona, G.; Trimarchi, G.; Barberi, I. Effects of melatonin treatment in septic newborns. Pediatr. Res., 2001, 50, 756-760.
84. Nunes O.S.; Pereira R.S. Regression of herpes viral infection symptoms using melatonin and SB-73: comparison with Acyclovir. J. Pineal Res., 2008, 44, 373-378.
85. Cos, S.; Sanchez-Barcelo, E.J. Melatonin and mammary pathological growth. Front. Neuroendocrinol., 2000, 21, 133-170.
86. Blask, D.E.; Dauchy, R.T.; Sauer L.A. Putting cancer to sleep at night: the neuroendocrine/ circadian melatonin signal. Endocrinology, 2005, 27, 178-188.
87. Korkmaz, A.; Sanchez-Barcelo, E.J.; Tan, D.X.; Reiter, R.J. Role of melatonin in the epigenetic regulation of breast cancer. Breast Cancer Res. Treat., 2009, 115, 13-27.
88. Jung, B.; Ahmad, N. Melatonin in cancer management: progress and promise. Cancer Res., 2006; 66, 9789-9793.
89. Witt-Enderby, P.A.; Radio N.M.; Doctor J.S.; Davis, V.L. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J. Pineal Res., 2006, 41, 297-305.
90. Sánchez-Barceló, E.J.; Cos, S.; Mediavilla, D.; Martínez-Campa, C.; González, A.; Alonso-González, C. Melatonin-estrogen interactions in breast cancer. J. Pineal Res., 2005, 38, 217-222.
91. Cos, S.; González, A.; Martínez-Campa, C.; Mediavilla, M.D.; Alonso-González, C.; Sánchez-Barceló, E.J. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect. Prev., 2006, 30, 118-28.
92. Cos, S.; Garcia-Bolado, A.; Sánchez-Barceló, E.J. Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19). Melanoma Res., 2001, 11, 197-201.
93. Grant, S.G.; Melan, M.A.; Latimer, J.J.; Witt-Enderby, P.A. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev. Mol. Med., 2009, 11, 1-15.
94. Mediavilla, M.D.; Cos, S.; Sánchez-Barceló, E.J. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci., 1999, 65, 415-20.
95. Radio, N.M.; Doctor, J.S.; Witt-Enderby, P.A. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J. Pineal Res., 2006, 40, 332-342.
96. Cos, S.; Fernández, R.; Güézmes, A.; Sánchez-Barceló, E.J. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res., 1998, 58, 4383-4390.
97. Mediavilla, M.D.; Güezmez, A.; Ramos, S.; Kothari, L.; Garijo, F.; Sánchez-Barceló, E.J. Effects of melatonin on mammary gland lesions in transgenic mice overexpressing N-ras proto-oncogene. J. Pineal Res., 1997, 22, 86-94.
98. Rato, A.G.; Pedrero, J.G.; Martinez, M.A.; del Rio, B.; Lazo, P.S.; Ramos, S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J., 1999, 13, 857-868.
99. del Río, B.; García Pedrero, J.M.; Martínez-Campa, C.; Zuazua, P.; Lazo, P.S.; Ramos, S. Melatonin, an endogenousspecific inhibitor of estrogen receptor alpha via calmodulin. J. Biol. Chem., 2004, 279, 38294-38302.
100. Carrillo-Vico, A.; García-Mauriño, S.; Calvo, J.R.; Guerrero, J.M. Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J., 2003, 17, 755-757.
101. Leon-Blanco, M.M.; Guerrero, J.M.; Reiter, R.J.; Calvo, J.R.; Pozo, D. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J.Pineal Res., 2003, 35, 204-211.
102. Martínez-Campa, C.M.; Alonso-González, C.; Mediavilla, M.D.; Cos, S.; González, A.; Sanchez-Barcelo, E.J. Melatonin downregulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett., 2008, 268, 272-277.
103. Tan, D.X.; Reiter, R.J.; Manchester, L.C.; Yan, M.T.; El-Sawi, M.; Sainz, R.M.; Mayo, J.C.; Allegra, M.; Hardeland, R. Curr. Topics Med. Chem., 2007, 2, 181-198.
104. Gonzalez, A.; Cos, S.; Martinez-Campa, C.; Alonso-Gonzalez, C.; Sanchez-Mateos, S.; Mediavilla, M.D.; Sanchez-Barcelo, E.J. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J. Pineal Res., 2008, 45, 86-92.
105. Cos, S.; González, A.; Güezmes, A.; Mediavilla, M.D.; Martínez-Campa, C.; Alonso-González, C.; Sánchez-Barceló, E.J. Int. J. Cancer., 2006, 118, 274-278.
106. Panzer, A.; Viljoen, M. The validity of melatonin as an oncostatic agent. J. Pineal Res., 1997, 22, 184-202.
107. Mills, E.; Wu, P.; Seely, D.; Guyatt, G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J. Pineal Res., 2005, 39, 360-366.
108. Barni, S.; Lissoni, P.; Cazzaniga, M.; Ardizzoia, A.; Meregalli, S.; Fossati, V.; Fumagalli, L.; Brivio, F.; Tancini, G. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology, 1995, 52, 243-245.
109. Lissoni, P.; Barni, S.; Tancini, G.; Mainini, E.; Piglia, F.; Maestroni, G.J.; Lewinski, A. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology, 1995, 52, 163-1666.
110. Lissoni, P.; Barni, S.; Brivio, F.; Rossini, F.; Fumagalli, L.; Ardizzoia, A.; Tancini, G.A. A biological study on the efficacy of lowdose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology, 1995, 52, 360-362.
111. Lissoni, P.; Pittalis, S.; Ardizzoia, A.; Brivio, F.; Barni, S.; Tancini, G.; Pelizzoni, F.; Maestroni, G.J.; Zubelewicz, B.; Braczkowski, R. Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. Support Care Cancer, 1996, 4, 313-316.
112. Lissoni, P.; Paolorossi, F.; Tancini, G.; Barni, S.; Ardizzoia, A.; Brivio F.; Zubelewicz, B.; Chatikhine, V. Is there a role for melatonin in the treatment of neoplastic cachexia? Is there a role for melatonin in the treatment of neoplastic cachexia? Eur. J. Cancer, 1996, 32, 1340-1343.
113. Lissoni, P.; Cazzaniga, M.; Tancini, G.; Scardino, E.; Musci, R.; Barni, S.; Maffezzini, M.; Meroni, T.; Rocco, F.; Conti, A.; Maestroni, G. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Eur. Urol., 1997, 31, 178-181.
114. Lissoni, P.; Paolorossi, F.; Ardizzoia, A.; Barni, S.; Chilelli, M.; Mancuso, M.; Tancini, G.; Conti, A.; Maestroni, G.J. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J. Pineal Res., 1997, 23, 15-19.
115. Lissoni, P.; Tancini, G.; Paolorossi, F.; Mandalà, M.; Ardizzoia, A.; Malugani, F.; Giani, L.; Barni, S. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J. Pineal Res., 1999, 26, 169-173.
116. Lissoni, P.; Barni, S.; Mandalà, M.; Ardizzoia, A.; Paolorossi, F.; Vaghi, M.; Longarini, R.; Malugani, F.; Tancini, G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur. J. Cancer, 1999, 35, 1688-1692.
117. Lissoni, P.; Mandalà, M.; Brivio, F. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin. Eur. Urol., 2000, 38, 115-118.
118. Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anti Cancer Res., 2003, 23, 1951-1954.
119. Shiu, S.Y.; Law, I.C.; Lau, K.W.; Tam, P.C.; Yip, A.W.; Ng, W.T. Melatonin slowed the early biochemical progression of hormonerefractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J. Pineal Res., 2003, 35, 177-182.
120. Lissoni, P.; Chilelli, M.; Villa, S.; Cerizza, L.; Tancini, G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J. Pineal Res., 2003, 35, 12-15.
121. Lissoni, P.; Malugani, F.; Brivio, F.; Piazza, A.; Vintimilla, C.; Giani, L.; Tancini, G. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study. Neuro Endocrinol. Lett., 2003, 24, 259-62.
122. Norsa, A.; Martino, V. Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. Cancer Biother. Radiopharm., 2007, 22, 50-55.
123. Lissoni, P. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol. Biol., (Paris), 2007, 55, 198-200.
124. Lissoni, P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol. Biol., (Paris), 2007, 55, 201-204.
125. Lissoni, P., Rovelli, F.; Brivio, F.; Fumagalli, L.; Brera, G. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. In Vivo, 2008, 22, 397-400.
126. Lissoni, P.; Brivio, F.; Fumagalli, L.; Messina, G.; Vigoré, L.; Parolini, D.; Colciago, M.; Rovelli, F. Neuroimmunomodulation in medical oncology: Application of psychoneuroimmunology. Anticancer Res., 2008, 28, 1377-1381
127. Todisco, M. Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH. Cancer Biother. Radiopharm., 2009, 24, 353-355.
128. Reiter, R.J.; Tan, D.X.; Sainz, R.M.; Mayo, J.C. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol., 2002, 54, 1299-1321.
129. Schernhammer, E.; Chen, H.; Ritz, B. Circulating melatonin levels: possible link between Parkinsońs disease and cancer risk? Cancer Causes Control, 2006, 17, 577-582.
130. Christofides, J.; Bridel, M.; Egerton, M.; Mackay, G.M.; Forrest, C.M.; Stoy, N.; Darlington, L.G.; Stone, T.W. Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury. J. Neurochem., 2006, 97, 1078-1088.
131. Rocchitta, G.; Migheli, R.; Esposito, G.; Marchetti, B.; Desole, M.S.; Miele, E.; Serra, P.A. Endogenous melatonin. LDOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinsońs disease. J. Pineal Res., 2006, 40, 204-213.
132. Brunner, P.; Sözer-Topcular, N.; Jockers, R.; Ravid, R.; Angeloni, D.; Fraschini, F.; Eckert, A.; Müller-Spahn, F.; Savaskan, E. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Eur. J. Histochem., 2006, 50, 311-316.
133. Brusco, L.I.; Márquez, M.; Cardinali, D.P. Monozygotic twins with Alzheimer's disease treated with melatonin: Case report. J. Pineal Res., 1998, 25, 260-263
134. Jean-Louis, G.; Zizi, F.; von Gizycki. H.; Taub, H. Percept. Mot. Skills, 1998, 87, 331-339.
135. Asayama, K.; Yamadera, H.; Ito, T.; Suzuki, H.; Kudo, Y.; Endo, S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J. Nippon Med. Sch., 2003, 70, 334-341.
136. Singer, C.; Tractenberg, R.E.; Kaye J.; Schafer, K.; Gamst, A.; Grundman, M.; Thomas, R.; Thal, L.J. Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep, 2003, 26, 893-901.
137. Gehrman, P.R.; Connor, D.J.; Martin, J.L.; Shochat, T; Corey-Bloom, J.; Ancoli-Israel, S. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am. J. Geriatr. Psychiatry, 2009, 17, 166-169.
138. Furio, A.M.; Brusco, L.I.; Cardinali, D.P. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J. Pineal Res., 2007, 43, 404-409.
139. Dowling, G.A.; Burr, R.L.; van Someren, E.J.; Hubbard, E.M.; Luxenberg, J.S.; Mastick, J.; Cooper, B.A. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J. Am. Geriatr. Soc., 2008, 56, 239-246.
140. Zisapel, N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol. Neurobiol., 2001, 21, 605-616.
141. Willis, G.L.; Armstrong, S.M. A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol. Behav., 1999, 66, 785-795.
142. Willi, G.L.; Robertson, A.D. Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmacol. Biochem. Behav., 2004, 79, 413-429.
143. Paus, S.; Schmitz-Hübsch, T.; Wüllner, U.; Vogel, A.; Klock-Gether, T.; Abele, M. Bright light therapy in Parkinson's disease: A pilot study. Mov. Disord., 2007, 22, 1495-1498.
144. Saravanan, K.S.; Sindhu, K.M.; Mohanakumar, K.P. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J. Pineal Res., 2007, 42, 247-253.
145. +-induced caspase-mediated death pathway and DNA fragmentation factor-45 cleavage in SK-N-SH cultured cells. J. Pineal Res,. 2007, 43, 115-120.
146. Sharma, R.; Mc Millan, C.R.; Niles, L.P. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease. J. Pineal Res., 2007, 43, 245-254.
147. Alvira, D.; Tajes, M.; Verdaguer, E.; Acuña-Castroviejo, D.; Folch, J.; Camins, A.; Pablos, M. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J. Pineal Res., 2006, 40, 251-258.
148. Tan, D.X.; Manchester, L.C.; Sainz, R.M.; Mayo, J.C.; Alvarez, F.; Reiter, R.J. Antioxidant strategies in protection against neurodegenerative disorders. Expert Opin. Ther. Patents, 2003, 13, 1513-1543.
149. Brusco, L.I.; Fainstein, I.; Márquez, M.; Cardinali, D.P. Effect of melatonin in selected populations of sleep-disturbed patients. Biol. Signals Recept., 1999, 8, 126-131.
150. Dowling, G.A.; Mastick, J.; Colling, E.; Carter, J.H.; Singer, C.M.; Aminoff, M.J. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med., 2005, 6, 459-466.
151. Medeiros, C.A.; Carvalhedo de Bruin, P.F.; Lopes, L.A.; Magal-Hães, M.C.; de Lourdes Reabra, M.; de Bruin, V.M. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's-disease. A randomized, double blind, placebo-controlled study. J. Neurol., 2007, 254, 459-64.
152. Weishaupt, J.H.; Bartels, C.; Pölking, E.; Dietrich, J.; Rohde, G.; Poeggeler, B.; Mertens, N.; Sperling, S.; Bohn, M.; Hüther, G.; Schneider, A.; Bach, A.; Sirén, A.; Hardeland, R.; Bähr, M.; Nave, K.A.; Ehrenreich, H. Reduced oxidative damage in ALS by highdose enteral melatonin treatment. J. Pineal Res., 2006, 41, 313-23.
153. Hancock, E.; O'Callaghan, F.; Osborne, J.P. Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex. J. Child Neurol., 2005, 20, 78-80.
154. Riemersma-van der Lek, R.F.; Swaab, D.F.; Twisk, J.; Hol, E.M.; Hoogendijk, W.J.; Van Someren, E.J. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a andomized controlled trial. JAMA, 2008, 299, 2642-2655.
155. Reiter, R.J.; Blask, D.E.; Talbot, J.A.; Barnet, M.P. Nature and the time course of seizures associated with surgical removal of the pineal gland from parathyroidectomized rats. Exp. Neurol., 1973, 38, 386-397.
156. Fariello, R.G.; Bubenik, G.A.; Brown, G.M.; Gorta, L.J. Epileptogenic action of intraventricularly injected antimelatonin antibody. Neurology, 1977, 27, 267-270.
157. Manev, H.; Uz, T.; Kharlamov, A.; Joo, J-Y. Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J., 1996, 10, 1546-1551.
158. Muñoz-Hoyos, A.; Sánchez-Forte, M.; Molina-Carballo, A.; Escames, G.; Martin-Medina, E.; Reiter, R.J.; Molina-Font, J.A.; Acuña-Castroviejo, D. Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. J. Child Neurol., 1998, 13, 501-509.
159. Molina-Carballo, A.; Muñoz-Hoyos, A.; Sánchez-Forte, M.; Ube-ros-Fernández, J.; Moreno-Madrid, F.; Acuña-Castroviejo, D. Melatonin increases following convulsive seizures may be related to its anticonvulsant properties at physiological concentrations. Neuropediatrics, 2007, 38, 122-125.
160. Molina-Carballo, A.; Muñoz-Hoyos, A.; Reiter, R.J.; Sánchez-Forte, M.; Moreno-Madrid, F.; Rufo-Campos, M.; Molina-Font, J.A.; Acuña-Castroviejo D. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years experience. J. Pineal Res., 1997, 23, 97-105.
161. Peled, N.; Shorer, Z.; Peled, E.; Pillar, G. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia, 2001, 42, 1208-1210.
162. Saracz, J.; Rosdy, B. Effect of melatonin on intractable epilepsies. Orv. Hetil., 2004, 145, 2583-2587.
163. Fauteck, J.; Schmidt, H.; Lerchl, A.; Kurlemann, G.; Wittkowski, W. Melatonin in epilepsy: first results of replacement therapy and first clinical results. Biol. Signals Recept., 1999, 8, 105-110.
164. Sheldon, S.H. Proconvulsant effects of oral melatonin in neurologically disabled children. Lancet, 1998, 351, 1254.
165. Sandyk, R.; Tsagas, N.; Anninos, P.A. Melatonin as a proconvulsive hormone in humans. Int. J. Neurosci., 1992, 63, 125-135.
166. Gupta, M.; Gupta, Y.K.; Agarwal, S.; Aneja, S.; Kalaivani, M.; Kohli, K. Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized, double-blind,placebo-controlled trial. Epilepsia, 2004, 45, 1636-1639.
167. Gupta, M.; Gupta Y.K.; Agarwal, S.; Aneja, S.; Kohli, K. A randomized, double-blind, placebo controlled trial of melatonin addon therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes.Br. J. Clin. Pharmacol., 2004, 58, 542-547.
168. Gupta, M.; Aneja, S.; Kohli, K. Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsy Behav., 2004, 5, 316-321.
169. Coppola, G.; Iervolino, G.; Mastrosimone, M.; La Torre, G.; Ruiu, F.; Pascotto A. Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain Dev., 2004, 26, 373-376.
170. Deshmukh, V.D. Retino-hypothalamic-pineal hypothesis in the pathophysiology of primary headaches. Med. Hypotheses., 2006, 66, 1146-1151.
171. Peres, M.F. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia, 2005, 25, 403-411.
172. Claustrat, B.; Loisy, C.; Brun, J.; Beorchia, S.; Arnaud, J.L.; Cha-Zot, G. Nocturnal plasma melatonin levels in migraine: a preliminary report. Headache, 1989, 29, 242-245.
173. Claustrat, B.; Brun, J.; Geoffriau, M.; Zaidan, R.; Mallo, C.; Cha-zot, G. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia, 1997, 17, 511-517.
174. Nagtegaal, J.E.; Smits, M.G.; Swart, A.C.; Kerkhof, G.A.; van der Meer, Y.G. Melatonin-responsive headache in delayed sleep phase syndrome: preliminary observations. Headache,1998, 38, 303-307.
175. Leone, M.; D'Amico, D.; Moschiano, F.; Fraschini, F.; Bussone, G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia, 1996, 16, 494-496.
176. Peres, M.F.; Rozen, T.D. Melatonin in the preventive treatment of chronic cluster headache. Cephalalgia, 2001, 21, 993-995.
177. Rozen, T.D. Melatonin as treatment for idiopathic stabbing headache. Neurology, 2003, 61, 865-866.
178. Miano, S.; Parisi, P.; Pelliccia, A.; Luchetti, A.; Paulino, M.C.; Villa, M.P. Melatonin to prevent migraine or tension-type headache in children. Neurol. Sci., 2008, 29, 285-287.
179. Jan, J.E.; Reiter, R.J.; Wasdell, M.B.; Bax, M. J. Pineal Res., 2009, 46, 1-7.
180. Sack, R.L.; Auckley, D.; Auger, R.R.; Carskadon, M.A.; Wright, K.P.; Vitiello, M.V.; Zhdanova, I.V. Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. Sleep, 2007, 30, 1460-1483.
181. Schulz, P.; Steimer, T. Neurobiology of circadian systems. CNS Drugs, 2009, 23, 3-13.
182. Redman, J.; Armstrong, S.; Ng, K.T. Free-running activity rhythms in the rat: entrainment by melatonin. Science, 1983, 219, 1089-1091.
183. Lewy, A.J.; Ahmed, S.; Jackson, J.M.; Sack, R.L. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol. Int., 1992, 9, 380-392.
184. Tzischinsky, O.; Shlitner, A.; Lavie, P. The association between the nocturnal sleep gate and nocturnal onset of urinary 6-sulphatoxymelatonin. J. Biol. Rhythms, 1993, 8, 199-209.
185. Zhdanova, I.V.; Wurtman, R.J. Efficacy of melatonin as a sleeppromoting agent. J. Biol. Rhythms, 1997, 112, 644-50.
186. Brzezinski, A. Melatonin in humans. N. Engl. J. Med., 1997, 336, 186-195.
187. Krauchi, K.; Wirtz-Justice, A. Circadian clues to sleep onset mechanisms. Neuropsychopharmacology, 2001, 25, 92-96.
188. Turek, F.W.; Gillette, M.U. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med., 2004, 5, 523-532.
189. Arendt, J.; Skene, D.J.; Middleton, B.; Lockley, S.W.; Deacon, S. Efficacy of melatonin treatment in jet-lag, shift work and blindness. J. Biol. Rhythms, 1997, 12, 604-617.
190. Wyatt, J.K.; Dijk, D.J.; Ritz-de Cecco, A.; Ronda, J.M.; Czeisler, C.A. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep, 2006, 29, 609-618.
191. Sánchez-Barcelo, E.J.; Martinez-Campa, C.M.; Mediavilla, M.D.; Gonzalez, A.; Alonso-Gonzalez, C.; Cos, S. Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists. Rec. Patents Endocr. Metab. Immune Drug Disc., 2007, 1, 142-151.
192. Herxheimer, A.; Petrie, KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst. Rev., 2002, 2, Art. CD001520.
193. Waterhouse, J. Jet lag: trends and coping strategies. Lancet, 2007, 369, 1117-1129.
194. Spitzer, R.L.; Terman, M.;Williams, J.B.; Terman, J.S.; Malt, U.F.; Singer, F.; Lewy, A.J. Jet lag: clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial. Am. J. Psychiatry, 1999, 156, 1392-1396.
195. Edwards, B.J.; Atkinson, G.; Waterhouse, J.; Reilly, T.; Godfrey, R.; Budgett, R. Use of melatonin in recovery from jet-lag following an eastward flight across 10 time-zones. Ergonomics, 2000, 43, 1501-1513.
196. Arendt, J.; Aldhous, M.; Marks, V. Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial. BMJ, 1986, 292, 1170.
197. Petrie, K.; Conaglen, J.V.; Thompson, L.; Chamberlain, K. Effect of melatonin on jet lag after long haul flights. BMJ, 1989, 298, 705-707.
198. Claustrat, B.; Brun, J.; David, M.; Sassolas, G.; Chazot, G. Melatonin and jet lag: confirmatory result using a simplified protocol. Biol. Psychiatry, 1992, 32, 705-711.
199. Petrie, K.; Dawson, A.G.; Thompson, L.; Brook, R. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol. Psychiatry, 1993, 33, 526-530.
200. Comperatore, C.A.; Lieberman, H.R.; Kirby, A.W.; Adams, B.; Crowley, J.S. Melatonin efficacy in aviation missions requiring rapid deployment and night operations. Aviat. Space Environ. Med., 1996, 67, 520-524.
201. Suhner, A.; Schlagenhauf, P.; Johnson, R.; Tschopp, A.; Steffen, R. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. Chronobiol. Int., 1998, 15, 655-666.
202. Suhner, A.; Schlagenhauf, P.; Hofer, I.; Johnson, R.; Tschopp, A.; Steffen, R. Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. Aviat. Space Environ. Med., 2001, 72, 638-646.
203. Beaumont, M.; Batejat, D.; Pierard, C.; Van Beers, P.; Denis, J.B.; Coste, O.; Doireau, P.; Chauffard, F.; French, J.; Lagarde, D. Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. J. Appl. Physiol., 2004, 96, 50-58.
204. Pierard, C; Beaumont, M.; Enslen, M.; Chauffard, F.; Tan, D.X.; Reiter, R.J.; Fontan, A.; French, J.; Coste, O.; Lagarde, D. Resynchronization of hormonal rhythms after an eastbound flight in humans: effects of slow-release caffeine and melatonin. Eur. J. Appl. Physiol., 2001, 85, 144-150.
205. Paul, M.A.; Gray, G.; Sardana, T.M.; Pigeau, RA. Melatonin and zopiclone as facilitators of early circadian sleep in operational air transport crews. Aviat. Space Environ. Med., 2004, 75, 439-443.
206. Cardinali, D.P.; Bortman, G.P.; Liotta, G.; Pérez Lloret, S.; Albornoz, L.E.; Cutrera, R.A.; Batista, J.; Ortega Gallo, P. A multifactorial approach employing melatonin to accelerate resynchronization of sleep-wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. J. Pineal Res., 2002, 32, 41-46.
207. Sack, R.L.; Lewy, A.J. Melatonin as a chronobiotic: treatment of circadian desynchrony in night workers and the blind. J. Biol. Rhythms, 1997, 12, 595-603.
208. Smith, M.R.; Lee, C.; Crowley, S.J.; Fogg, L.F.; Eastman, C.I. Morning melatonin has limited benefit as a soporific for daytime sleep after night work. Chronobiol. Int., 2005, 22, 873-888.
209. Folkard, S.; Arendt, J.; Clark, M. Can melatonin improve shift workers' tolerance of the night shift? Some preliminary findings. Chronobiol. Int., 1993, 10, 315-320.
210. Sadeghniiat-Haghighi, K.; Aminian, O.; Pouryaghoub, G.; Yazdi, Z. Efficacy and hypnotic effects of melatonin in shift-work nurses: double-blind,placebo-controlled crossover trial. J. Circadian Rhythms., 2008, 29, 6-10.
211. James, M.; Tremea, M.O.; Jones, J.S.; Krohmer, J.R. Can melatonin improve adaptation to night shift? Am. J. Emerg. Med., 1998, 16, 367-370.
212. Jorgensen, K.M.; Witting, M.D. Does exogenous melatonin improve day sleep or night alertness in emergency physicians working night shifts? Ann. Emerg. Med., 1998, 31, 699-704.
213. Yoon, I.Y.; Song, B.G. Role of morning melatonin administration and attenuation of sunlight exposure in improving adaptation of night-shift workers. Chronobiol. Int., 2002, 19, 903-913.
214. Bjorvatn, B.; Stangenes, K.; Oyane, N.; Forberg, K.; Lowden, A.; Holsten, F.; Akerstedt, T. Randomized placebo-controlled field study of the effects of bright light and melatonin in adaptation to night work. Scand. J. Work Environ. Health, 2007, 33, 204-214.
215. Aeschbach, D.; Lockyer, B.J.; Dijk, D.J.; Lockley, S.W.; Nuwayser, E.S.; Nichols, L.D.; Czeisler, C.A. Use of transdermal melatonin delivery to improve sleep maintenance during daytime. Clin. Pharmacol. Ther., 2009, 86, 378-38.
216. Mundey, K.; Benloucif, S.; Harsanyi, K.; Dubocovich, M.L.; Zee, P.C. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep, 2005, 28, 271-1278.
217. Didden, R.; Korzilius, H.; van Aperlo, B.; van Overloop, C.; de Vries, M. Sleep problems and daytime problembehaviours in children with intellectual disability. J. Intellect. Disabil. Res., 2002, 46, 537-547.
218. Weiss, M.D.; Wasdell, M.B.; Bomben, M.M.; Rea, K.J.; Freeman, R.D. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J. Am. Acad. Child Adolesc. Psychiatry, 2006, 45, 512-519.
219. Galli-Carminati, G.; Deriaz, N.; Bertschy, G. Melatonin in treatment of chronic sleep disorders in adults with autism: a retrospective study. Swiss Med. Wkly., 2009, 139, 293-296.
220. Braam, W.; Smits, M.G.; Didden, R.; Korzilius, H.; Van Geijlswijk, I.M.; Curfs, L.M. Exogenous melatonin for sleep problems in individuals with intellectual dissability: a meta-analysis. Dev. Med. Child Neurol., 2009, 51, 340-349.
221. Leersnyder, H.D.; Bresson, J.L.; Blois, M.C.; Souberbielle, J.C.; Mogenet, A.; Delhotal-Landes, B.; Salefranque, F.; Munnich, A. Adrenergic antagonist and melatonin reset the clock and restore sleep in a circadian disorder, Smith-Magenis syndrome. J. Med. Genet., 2003, 40, 74-78.
222. Leersnyder, H.D.; Claustrat, B.; Munnich, A.; Verloes, A. Circadian rhythm disorder in a rare disease: Smith-Magenis syndrome. Mol. Cell Endocrinol., 2006, 252, 88-91.
223. Carpizo, R.; Martínez, A.; Mediavilla, D.; González, M.; Abad, A.; Sánchez-Barceló, E.J. Smith-Magenis syndrome: a case report of improved sleep after treatment with 1-adrenergic antagonists and melatonin. J. Pediatrics, 2006, 149, 409-11.
224. Garfinkel, D.; Zisapel, N.; Wainstein, J.; Laudon, M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch. Intern. Med., 1999, 159, 2456-2460.
225. Garzón, C.; Guerrero, J.M.; Aramburu, O.; Guzmán, T. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, doubleblind, placebo-controlled study. Aging Clin. Exp. Res., 2009, 21, 38-42.
226. Luthringer, R.; Muzet, M.; Zisapel, N.; Staner, L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int. Clin. Psychopharmacol., 2009, 24, 239-249.
227. Baskett, J.J.; Broad, J.B.; Wood, P.C.; Duncan, J.R.; Pledger, M.J.; English, J.; Arendt, J. Does melatonin improve sleep in older people? A randomised crossover trial. Ageing, 2003, 32, 164-170.
228. Gubin, D.G.; Gubin, G.D.; Waterhouse, J.; Weinert, D. The circadian body temperature rhythm in the elderly: effect of single daily melatonin dosing. Chronobiol. Int., 2006, 23, 639-658.
229. Peles, E.; Hetzroni, T.; Bar-Hamburger, R.; Adelson, M.; Schreiber, S. Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial. Addiction, 2007, 102, 1947-1953.
230. Reiter, R.J.; Paredes, S.D.; Korkmaz, A.; Manchester, L.C.; Tan, D.X. Melatonin in relation to the strong and weak versions of the free radical theory of aging. Adv. Med. Sci., 2008, 53, 119-29.
231. Karasek, M. Does melatonin play a role in aging processes? J. Physiol. Pharmacol., 2007, 58, 105-113.
232. Bellipanni, G.; Bianchi, P.; Pierpaoli, W.; Bulian, D.; Ilyia, E. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp. Gerontol., 2001, 36, 297-310.
233. Carman, J.S.; Post, R.M.; Buswell, R.; Goodwin, F.K. Negative effects of melatonin on depression. Am. J. Psychiatry., 1976, 133, 1181-1186.
234. Wirz-Justice, A.; Graw, P.; Kräuchi, K.; Gisin, B.; Arendt, J.; Aldhous, M.; Pöldinger, W. J. Morning or night-time melatonin is ineffective in seasonal affective disorder. Psychiatr. Res., 1990, 24, 129-137.
235. Dolberg, O.T.; Hirschmann, S.; Grunhaus, L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am. J. Psychiatry, 1998, 155, 1119-1121.
236. Lewy, A.J.; Bauer, V.K.; Cutler, N.L.; Sack, R.L. Melatonin treatment of winter depression: a pilot study. Psychiatry Res., 1998, 77, 57-61.
237. Leppämäki, S.; Partonen, T.; Vakkuri, O.; Lönnqvist, J.; Partinen, M.; Laudon, M. Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour. Eur. Neuro-psychopharmacol., 2003, 13, 137-145.
238. Ebadi, M.; Govitrapong, P.; Phansuwan-Pujito, P.; Nelson, F.; Reiter, R.J. Pineal opioid receptors and analgesic action of melatonin. J. Pineal Res., 1998, 24, 193-200.
239. Caumo, W.; Torres, F.; Moreira, N.L.; Auzani, J.A.; Monteiro, C.A.; Londero, G.; Ribeiro, D.F.; Hidalgo, M.P. The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy. Anesth. Analg., 2007, 105, 1263-1271.
240. Naguib, M.; Samarkandi, A.H. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study Anesth. Analg., 2000, 91, 473-479.
241. Acil, M.; Basgul, E.; Celiker, V.; Karagöz, A.H.; Demir, B.; Aypar, U. Perioperativeeffects of melatonin and midazolam premedication on sedation, orientation, anxiety scores and psychomotor performance. Eur. J. Anaesthesiol., 2004, 21, 553-557.
242. Capuzzo, M.; Zanardi, B.; Schiffino, E.; Buccoliero, C.; Gragnaniello, D; Bianchi, S.; Alvisi, R. Melatonin does not reduce anxiety more than placebo in the elderly undergoing surgery. Anesth. Analg., 2006, 103, 121-123.
243. Kain, Z.N.; MacLaren, J.E.; Herrmann, L.; Mayes, L.; Rosenbaum, A.; Hata, J.; Lerman, J. Preoperative melatonin and its effects on induction and emergence in children undergoing anesthesia and surgery. Anesthesiology, 2009, 111, 44-49.
244. Isik, B.; Baygin, O.; Bodur, H. Premedication with melatonin vs midazolam in anxious children. Paediatr. Anaesth., 2008, 18, 635-641.
245. Samarkandi, A.; Naguib, M.; Riad, W.; Thalaj, A.; Alotibi, W.; Aldammas, F.; Albassam, A. Melatonin vs. midazolam premedication in children: a double-blind, placebo-controlled study. Eur. J. Anaesthesiol., 2005, 22, 189-196.
246. Schmidt, C.M.; Knief, A.; Deuster, D.; Matulat, P.; Zehnhoff-Dinnesen, A.G. Melatonin is a useful alternative to sedation in children undergoing brainstem audiometry with an age dependent success rate-a field report of 250 investigations. Neuropediatrics, 2007, 38, 2-4.
247. Sury, M.R.; Fairweather, K. The effect of melatonin on sedation of children undergoing magnetic resonance imaging. Br. J. Anaesth. 2006, 97, 220-225.
248. Mowafi, H.A.; Ismail, S.A. Melatonin improves tourniquet tolerance and enhances postoperative analgesia in patients receiving intravenous regional anesthesia. Anesth. Analg., 2008, 107, 1422-6.
249. Naguib, M.; Samarkandi, A.H.; Moniem, M.A.; Mansour, E.D.; Alshaer, A.A.; Al-Ayyaf, H.A.; Fadin, A.; Alharby, S.W. The effects of melatonin premedication on propofol and thiopental induction dose-response curves: a prospective, randomized,double-blind study. Anesth. Analg., 2006, 103, 1448-1452.
250. Turkistani, A.; Abdullah, K.M.; Al-Shaer, A.A.; Mazen, K.F.; Alkatheri, K. Melatonin premedication and the induction dose of propofol. Eur. J. Anaesthesiol., 2007, 24, 399-402.
251. Evagelidis, P.; Paraskeva, A.; Petropoulos, G.; Staikou, C.; Fassou laki, A. Melatonin premedication does not enhance induction of anaesthesia with sevoflurane as assessed by bispectral index monitoring. Singapore Med. J., 2009, 50, 78-81.
252. Caumo, W.; Levandovski, R.; Hidalgo, M.P. Preoperative anxiolytic effect ofmelatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: a double-blind, randomized, placebo-controlled study. J. Pain. 2009, 10, 100-108.
253. Hanania, M.; Kitain, E. Melatonin for treatment and prevention of postoperative delirium. Anesth. Analg., 2002, 94, 338-339.
254. Koch, B.C.; Nagtegaal, J.E.; Kerkhof, G.A.; Ter Wee, P.M. Circadian sleep-wake rhythm disturbances in end-stage renal disease. Nat. Rev. Nephrol., 2009, 5, 407-416.
255. Koch, B.C.; Nagtegaal, J.E.; Hagen, E.C.; van der Westerlaken, M.M.; Boringa, J.B.; Kerkhof, G.A.; Ter Wee, P.M. The effects of melatonin on sleep-wake rhythm of daytime haemodialysis patients:a randomized, placebo-controlled, cross-over study (EMSCAP study). Br. J. Clin. Pharmacol., 2009, 67, 68-75.
256. Herrera, J.; Nava, M.; Romero, F.; Rodríguez-Iturbe, B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am. J. Kidney Dis., 2001, 37, 750-757.
257. Labonia, W.; Rubio, D.; Arias, C. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients. Nephrology, (Carlton), 2005, 10, 583-587.
258. Reiter, R.J.; Tan, D.X.; Manchester, L.C.; Paredes, S.D.; Mayo, J.C.; Sainz, R.M. Melatonin and reproduction revisited. Biol. Reprod., 2009, 81, 445-456.
259. Tamura H, Takasaki A, Miwa I, Taniguchi K, Maekawa R, Asada H, Taketani T, Matsuoka A, Yamagata Y, Shimamura K, Morioka H, Ishikawa H, Reiter RJ, Sugino N. Oxidative stress impairs oocyte quality and melatonin protects oocytes from freeradical damage and improves fertilization rate. J. Pineal Res., 2008, 44, 280-287.
260. Gitto, E.; Reiter, J. R.; Cordaro, S. P.; La Rosa, M.; Chiurazzi, P.; Trimarchi, G.; Gitto, P.; Calabro, M. P.; Barberi, I. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am. J. Perinatol., 2004, 21, 209-216.
261. Gitto, E.; Romeo, C.; Reiter, R.J.; Impellizzeri, P.; Pesce, S.; Basile, M.; Antonuccio, P.; Trimarchi, G.; Gentile.; C.; Barberi, I.; Zuccarello, B. Melatonin reduces oxidative stress in surgical neonates. J. Pediatr. Surg., 2004, 39, 184-189.